Alkermes Plc

ALKS

NASDAQ. Currency in USD

25.24 -0.28 ( -1.10% )

Real time prices: December 19

Market Cap.
4.15B
Beta (5Y monthly)
0.61
Price/Earnings
59.26
EPS (TTM)
0.43
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.09M
1y Target Est.
31.78
Day's Range
24.80
-
25.60
52 Week's Range
21.75
-
32.79

Historical Summary

Performance
EPS growth
Share Buybacks

About Alkermes Plc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.alkermes.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
161.70M
Employees
2211
Address
Connaught House, Dublin, Ireland, 4
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Latest news

Analyst Ratings for Alkermes
Analyst Ratings for Alkermes

Over the past 3 months, 4 analysts have published their opinion on Alkermes (NASDAQ:ALKS) stock....
By Benzinga - 7 weeks ago

Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 8 weeks ago

How Alkermes (ALKS) Stock Stands Out in a Strong Industry
How Alkermes (ALKS) Stock Stands Out in a Strong Industry

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs...
By Zacks Investment Research - 9 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022

Upgrades According to Baird, the prior rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was changed from...
By Benzinga - 12 weeks ago

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the...
By Zacks Investment Research - 12 weeks ago

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely...
By Zacks Investment Research - 13 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022

Upgrades For Enviva Inc (NYSE:EVA), Citigroup upgraded the previous rating of Neutral to Buy. For...
By Benzinga - 15 weeks ago

Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday

Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst...
By Benzinga - 15 weeks ago